Abstract: ［Abstract］〓Objective〖HTSS〗〓To observe the shortterm efficacy and safety of the new targeted drug apatinib combined with chemotherapy in the treatment of patients with ovarian cancer recurrence.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 30 cases of patients with secondline treatment failure in advanced ovarian cancer were randomly divided into 2 groups： the observation group(n=10) and the control group(n=20).The patients with advanced ovarian cancer adopted a apatinib and taxel， anthracyclinesbased combination chemotherapy regimen as observation group. Concurrent other patients who did not receive apatinib were chosen as control group. The therapeutic efficacy and sideeffect of the two groups were compare. 
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After 6 cycles, clinical curative effect of observation group is better than the control group. There were significant differences in the objective response rate and the disease control rate(P＜005).The most common adverse reactions were handfoot syndrome, hypertension, flatulence and diarrhea, mainly in grade 1-2.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Apatinib combined with chemotherapy is an effective and welltolerated treatment for advanced ovarian cancer, and the adverse reaction were tolerable.

Key words: ovarian neoplasms, drug resistance, neoplasm, apatinib, drug therapy, combination